2018
Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation
Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.Peer-Reviewed Original ResearchConceptsBone sarcomasClinical trialsFerumoxytol-enhanced MRIImmune-targeted therapiesProspective clinical trialsYoung adult patientsDensity of CD68Biopsy/resectionClin Cancer ResTumor biopsy/resectionInstitutional review boardNoninvasive imaging techniquesPrecontrast scansTAM densityAdult patientsPilot patientsPediatric patientsPostcontrast MRIPostcontrast scansCancer immunotherapyMacrophage stainingTumor responseMRI 24Tumor groupMalignant tumors
2016
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.
Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.Peer-Reviewed Original ResearchConceptsBasis of RECISTWorld Health OrganizationTherapeutic responseStandard of referenceOverall survivalClinical outcomesTumor responseTumor measurementsThree-dimensional tumor measurementsResponse Evaluation CriteriaPrimary tumor sizeLog-rank testKaplan-Meier plotsTherapeutic response assessmentInstitutional review boardTumor volume measurementsVolume measurementsPatient survivalRetrospective studyCox regressionTumor sizeGroup criteriaBland-Altman analysisEwing's sarcomaMedical CenterHistology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas
Sethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTyrosine kinase inhibitorsTreatment optionsEfficacy of TKIsMulti-targeted tyrosine kinase inhibitorAlveolar soft part sarcomaKinase inhibitorsNon-GIST sarcomasSpectrum of sarcomasFirst-line treatmentEfficacy of imatinibSoft tissue sarcomasImportant clinical questionsPoor response ratesSoft part sarcomaTarget-specific agentsDermatofibrosarcoma protruberansUnresectable diseaseAdvanced sarcomasRECIST criteriaBone sarcomasClinical efficacyTissue sarcomasRare tumorPreclinical dataChemotherapeutic options